Last updated: 30 January 2024 at 5:01pm EST

Plc Gsk Net Worth




The estimated Net Worth of Plc Gsk is at least $1.5 Miliardo dollars as of 7 December 2023. Plc Gsk owns over 3,300,000 units of Pandion Therapeutics stock worth over $839,724,848 and over the last 20 years Plc sold PAND stock worth over $656,033,715.

Plc Gsk PAND stock SEC Form 4 insiders trading

Plc has made over 31 trades of the Pandion Therapeutics stock since 2012, according to the Form 4 filled with the SEC. Most recently Plc bought 3,300,000 units of PAND stock worth $16,500,000 on 7 December 2023.

The largest trade Plc's ever made was selling 32,005,260 units of Pandion Therapeutics stock on 20 May 2021 worth over $392,064,435. On average, Plc trades about 1,475,496 units every 85 days since 2004. As of 7 December 2023 Plc still owns at least 13,983,761 units of Pandion Therapeutics stock.

You can see the complete history of Plc Gsk stock trades at the bottom of the page.



What's Plc Gsk's mailing address?

Plc's mailing address filed with the SEC is 980 GREAT WEST ROAD, , BRENTFORD MIDDLESEX, X0, TW8 9GS.

Insiders trading at Pandion Therapeutics

Over the last 4 years, insiders at Pandion Therapeutics have traded over $0 worth of Pandion Therapeutics stock and bought 1,743,632 units worth $30,815,954 . The most active insiders traders include Plc Gsk, Capital Management, L.P.Kol... e Daniel J. Becker. On average, Pandion Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $9,518,646. The most recent stock trade was executed by Daniel J. Becker on 19 November 2020, trading 197,716 units of PAND stock currently worth $2,989,466.



What does Pandion Therapeutics do?



Complete history of Plc Gsk stock trades at Amicus Therapeutics Inc, Applied Genetic Technologies Corp, ChemoCentryx Inc, Concert Pharmaceuticals Inc, CRISPR Therapeutics AG, Genocea Biosciences Inc, HTG Molecular Diagnostics Inc, Innoviva Inc, Theravance Biopharma Inc, Wave Life Sciences, Quest Diagnostics, Spero Therapeutics Inc, Telesis Bio Inc, Liquidia Corp, Turning Point Therapeutics Inc, Morphic Inc, Fulcrum Therapeutics Inc, Progyny Inc, Bicycle Therapeutics plc, Principia Biopharma, Nkarta e Pandion Therapeutics

Persona
Trans.
Transazione
Prezzo totale
Plc Gsk
10% proprietario
Acquistare $16,500,000
7 Dec 2023
Plc Gsk
10% proprietario
Vendita $392,064,435
20 May 2021
Plc Gsk
10% proprietario
Acquistare $2,836,134
24 Jul 2020
Plc Gsk
10% proprietario
Acquistare $6,499,997
24 Jun 2019
Plc Gsk
10% proprietario
Acquistare $1,725,276
10 Feb 2014
Plc Gsk
Direttore
Acquistare $6,499,998
17 Jul 2020
Plc Gsk
Direttore
Acquistare $14,999,994
14 Jul 2020
Plc Gsk
10% proprietario
Vendita $91,844
14 Jul 2020
Plc Gsk
10% proprietario
Acquistare $5,399,996
28 May 2019
Plc Gsk
Direttore
Acquistare $4,999,980
21 May 2020
Plc Gsk
Direttore
Acquistare $7,999,965
10 Sep 2019
Plc Gsk
Direttore
Acquistare $5,850,000
22 Apr 2019
Plc Gsk
10% proprietario
Vendita $103,000,000
20 May 2020
Plc Gsk
10% proprietario
Acquistare $9,999,976
18 Oct 2019
Plc Gsk
Direttore
Acquistare $4,999,995
1 Jul 2019
Plc Gsk
10% proprietario
Vendita $85,845,421
16 Oct 2018
Plc Gsk
Acquistare $1,636,998
30 Jul 2018
Plc Gsk
10% proprietario
Acquistare $1,000,000
17 Jul 2018
Plc Gsk
10% proprietario
Acquistare $5,999,994
6 Nov 2017
Plc Gsk
10% proprietario
Acquistare $3,499,990
2 Jul 2018
Plc Gsk
10% proprietario
Vendita $3,045,000
27 Mar 2017
Plc Gsk
10% proprietario
Acquistare $5,111,484
11 May 2015
Plc Gsk
10% proprietario
Acquistare $931,000
24 Oct 2016
Plc Gsk
10% proprietario
Acquistare $931,000
24 Oct 2016
Plc Gsk
10% proprietario
Vendita $11,069,300
23 Feb 2015
Plc Gsk
10% proprietario
Vendita $1,057,000
10 Dec 2014
Plc Gsk
10% proprietario
Acquistare $1,245,144
1 Apr 2014
Plc Gsk
10% proprietario
Vendita $59,860,714
27 Oct 2014
Plc Gsk
10% proprietario
Acquistare $3,000,000
20 Nov 2013
Plc Gsk
10% proprietario
Acquistare $18,582,360
17 Jul 2012
Plc Gsk
Acquistare $490,000
19 Feb 2014


Pandion Therapeutics executives and stock owners

Pandion Therapeutics executives and other stock owners filed with the SEC include: